

RESEARCH ARTICLE

Treatment of Cutaneous Leishmaniasis Caused by *Leishmania aethiopica*: A Systematic Review

Johan van Griensven^{1*}, Endalamaw Gadisa², Abraham Aseffa², Asrat Hailu³, Abate Mulugeta Beshah⁴, Ermias Diro⁵

1 Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, **2** Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia, **3** School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia, **4** World Health Organization, Addis Ababa, Ethiopia, **5** Department of Internal Medicine, University of Gondar, Gondar, Ethiopia

* jvangriensven@itg.be



Abstract

Leishmania aethiopica is the etiological agent of cutaneous leishmaniasis (CL) in Ethiopia and can cause severe and complicated cases such as diffuse CL (DCL), mucocutaneous leishmaniasis or extensive CL, requiring systemic treatment. Despite the substantial burden, evidence-based treatment guidelines are lacking. We conducted a systematic review of clinical studies reporting on treatment outcomes of CL due to *L. aethiopica* in order to help identify potentially efficacious medications on CL that can be taken forward for clinical trials. We identified a total of 24 records reporting on 506 treatment episodes of CL presumably due to *L. aethiopica*. The most commonly used drugs were antimonials (n = 201), pentamidine (n = 150) and cryotherapy (n = 103). There were 20 case reports/series, with an overall poor study quality. We only identified two small and/or poor quality randomized controlled trials conducted a long time ago. There were two prospective non-randomized studies reporting on cryotherapy, antimonials and pentamidine. With cryotherapy, cure rates were 60–80%, and 69–85% with antimonials. Pentamidine appeared effective against complicated CL, also in cases non-responsive to antimonials. However, all studies suffered from methodological limitations. Data on miltefosine, paromomycin and liposomal amphotericin B are extremely scarce. Only a few studies are available on DCL. The only potentially effective treatment options for DCL seem to be antimonials with paromomycin in combination or pentamidine, but none have been properly evaluated. In conclusion, the evidence-base for treatment of complicated CL due to *L. aethiopica* is extremely limited. While antimonials remain the most available CL treatment in Ethiopia, their efficacy and safety in CL should be better defined. Most importantly, alternative first line treatments (such as miltefosine or paromomycin) should be explored. High quality trials on CL due to *L. aethiopica* are urgently needed, exploring group sequential methods to evaluate several options in parallel.

OPEN ACCESS

Citation: van Griensven J, Gadisa E, Aseffa A, Hailu A, Beshah AM, Diro E (2016) Treatment of Cutaneous Leishmaniasis Caused by *Leishmania aethiopica*: A Systematic Review. PLoS Negl Trop Dis 10(3): e0004495. doi:10.1371/journal.pntd.0004495

Editor: Hechmi Louzir, Institut Pasteur de Tunis, TUNISIA

Received: September 25, 2015

Accepted: February 7, 2016

Published: March 3, 2016

Copyright: © 2016 van Griensven et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing Interests: The authors have declared that no competing interests exist.

Author Summary

Cutaneous leishmaniasis (CL) refers to skin ulcers caused by the *Leishmania* parasite, which is transmitted by the bite of sandflies. In Ethiopia, CL is caused by the *Leishmania aethiopia* parasite. CL in Ethiopia can be associated with severe and complicated disease such as diffuse CL (DCL), which presents with multiple skin lesions spread over the body. For such severe cases, topically applied treatment is not sufficient and systemic treatment (given in tablets or via injections) is required. Although the total number of patients that suffer from CL in Ethiopia is high, there are no evidence-based treatment guidelines. We conducted a systematic review of clinical studies reporting on treatment outcomes of CL due to *L. aethiopia*. We identified a total of 24 records reporting on 506 treatment episodes of CL presumably due to *L. aethiopia*. The most commonly used drugs were antimonials, pentamidine, and cryotherapy. Most studies were case reports or case series. There were two small clinical trials and two prospective non-randomized studies. However, all studies had some methodological limitations. With cryotherapy, cure rates were 60–80%, and 69–85% with antimonials. Pentamidine appeared effective against complicated CL, also in cases that did not improve on antimonials. Data on miltefosine, paromomycin and liposomal amphotericin B are extremely scarce. Only a few studies were available on DCL. The evidence-base for treatment of complicated CL due to *L. aethiopia* is extremely limited. While antimonials remain the most available CL treatment in Ethiopia, more data on the efficacy and safety in CL are needed. High quality trials on CL due to *L. aethiopia* are urgently needed, evaluating treatments beyond antimonials. Interesting options in the short term are drugs such as miltefosine, paromomycin and liposomal amphotericin B, as they are currently available in Ethiopia for treatment of visceral leishmaniasis.

Introduction

Cutaneous leishmaniasis (CL) is a chronic infectious skin disease caused by a group of protozoan parasites of the *Leishmania* genus. The parasites are transmitted to humans via the bite of phlebotomine sandflies and predominantly target reticulo-endothelial cells [1]. CL can present with a spectrum of clinical manifestations. Ulcerative skin lesions occurring at the site of the bite of the sandfly is the most common cutaneous manifestation (localized CL—LCL). While usually healing spontaneously after several months, it remains disfiguring and stigmatizing and often heals with scarring. There are several more rare forms like diffuse CL (DCL), which is often difficult to treat [1]. Mucosal leishmaniasis (ML) or mucocutaneous CL (MCL) refers to an often destructive form with mucosal inflammation, which has been mainly reported in the New World—in association with *L. braziliensis* [1,2]—but also in the Old World [3]. At the global level, around one million cases of CL occur annually [4]. In the New World, *L. braziliensis* causes the largest CL burden, with Brazil most severely affected. In the Old World, most cases are found in the Middle East, North Africa, the Indian subcontinent and Central Asia [4].

While CL in the Old world is predominantly caused by *L. tropica* and *L. major*, it is still estimated that several ten thousands of cases are due to *L. aethiopia*. These predominantly occur in Ethiopia, and more exceptionally in Kenya. Within Ethiopia, the annual CL burden is estimated at around 20,000 to 40,000 cases per year [4], of which 99% is thought to be due to *L. aethiopia* [5]. A recent study estimated almost 30 million of Ethiopians to be at risk for CL [6]. CL in Ethiopia is a zoonotic disease, mainly occurring in the highland regions, involving rock

hyraxes as reservoir. The disease predominantly affects children, adolescents and young adults [7–10]. In the Northern part of Ethiopia, HIV coinfection rates of 5.6% have been reported [7]. An outbreak of CL has recently been described [11].

Clinical manifestations of *L. aethiopia* are particularly diverse and pleotropic, and a high genetic diversity has been documented as well [12]. Localized CL (LCL) is the most frequent manifestation, while mucocutaneous (MCL) and diffuse CL (DCL) is relatively common [7]. Compared to LCL, MCL is reportedly less responsive to treatment and is more disfiguring [1]. DCL is notorious for its chronic and progressive course and non-responsiveness to the common antileishmanial drugs. It is characterized by highly parasitized nodular lesions spread throughout the body and the failure to mount an effective antileishmanial immune response. Even if lesion regression can be obtained with chemotherapy, most cases of DCL will relapse after treatment discontinuation [1]. Outside Ethiopia, DCL is rare and occasionally seen linked to *L. amazonensis* and *L. mexicana* [1,13].

Since its occurrence is restricted to almost a single country with limited resources, research on this species has been relatively limited, especially over the last 10 to 20 years when commitments to combat neglected tropical diseases have been enhanced and major scientific and technological breakthroughs have occurred. In terms of treatment of *L. aethiopia*, the evidence base remains extremely limited. A Cochrane review published in 2008 identified not a single randomized clinical trial dedicated to CL in Ethiopia [14]. Nevertheless, *L. aethiopia* has particular features (the frequent occurrence of DCL and MCL) that imply a potentially higher need of systemic therapy, as compared to other species such as *L. major* or *L. tropica*. It is clear that randomized clinical trials are highly needed and should be undertaken. It is however less clear which interventions should be selected for prioritization in these studies. We conducted a systematic review including any type of clinical study reporting on outcomes in humans of drug treatment of CL due to *L. aethiopia*, in order to help identify potentially efficacious medications for CL that can be taken forward in clinical trials. Laboratory studies evaluating drug susceptibility of *L. aethiopia* against currently available antileishmanial drugs were reviewed as well.

Methods

Types of studies and search strategy

This review was conducted in line with the PRISMA guidelines; the PRISMA checklist was completed (See [S1 Checklist](#)) [15]. The sources searched and the search terms used are presented in Tables 1 and 2. Additional publications were identified by reviewing the reference lists of selected papers and by contacting experts in the field. As a first step, titles and abstracts were reviewed independently by two reviewers (JvG and ED) and those selected by at least one reviewer were included for evaluation of the full text. The final selection of studies to be included for data extraction was done independently by two reviewers (JvG and ED), with discrepancies solved by consensus. The scope of the review was any study in humans reporting on treatment outcomes of CL due to confirmed or presumed *L. aethiopia*. There was no selection based on patient age, sample size, study design, language or period. There was no selection by type of intervention (systemic, local, physical or other). Since the aim of this review was to prioritize interventions to be taken forward in phase III clinical trials, early studies on traditional therapies were not considered. No specific criteria were set for the outcome (treatment response), besides that the paper had to include at least some information on evolution after treatment. On some occasions, authors were contacted for additional information or clarifications. No specific protocol was developed for this systematic review.

Table 1. Search terms and date of first and latest search for the different electronic databases used.

Source	Search terms	Date of first and latest search ^a
Pubmed/Medline	See Table 2	2013/11/12–2015/09/20
Cochrane Register of Studies Cochrane Central Register of Controlled Trials (CENTRAL) CENTRAL		2015/09/20
Clinical trial.gov	Cutaneous leishmaniasis or cutaneous leishmania	2013/11/12–2015/09/20
Google scholar	(cutaneous leishmaniasis) (ethiopia OR aethiopica OR ethiopica) (treatment OR therapy)	2013/11/12–2015/09/20

^a First date is the date the search started; last date is the date the search was updated

doi:10.1371/journal.pntd.0004495.t001

Table 2. Medline search strategy.

Nr	Search terms
#1.	Leishmaniasis, Cutaneous/complications [Mesh]
#2.	Leishmaniasis, Cutaneous/drug therapy [Mesh]
#3.	Leishmaniasis, Cutaneous/epidemiology [Mesh]
#4.	Leishmaniasis, Cutaneous/therapy [Mesh]
#5.	Leishmaniasis, Cutaneous/surgery [Mesh]
#6.	Leishmaniasis/prevention and control [Mesh]
#7.	1-6/or
#8.	Ethiopia [Mesh]
#9.	Ethiopica (ALL) OR aethiopica (ALL)
#10.	8 or 9
#11.	7 and 9
#12.	therapy
#13.	treatment
#14.	Management
#15.	therapeutic use
#16.	drug therapy
#17.	drug treatment
#18.	clinical care
#19.	cryotherapy
#20.	Cryosurgery
#21.	12-20/or
#22.	leishmaniasis or leishmania or (oriental sore)
#23.	(visceral leishmaniasis) OR Leishmaniasis, visceral [MESH]
#24.	22 and 10
#25.	24 not 23
#26.	21 and 25
#27.	11 or 26

doi:10.1371/journal.pntd.0004495.t002

Data extraction and analysis

Data were extracted into pre-piloted tables by one reviewer (JvG) and verified by a second reviewer (ED), with discrepancies solved by consensus. Key outcome data were verified by duplicate extraction. The following information was extracted: 1) patient characteristics: age, sex, duration of lesions, type of CL (LCL, MCL or DCL); 2) whether the diagnosis was parasitologically confirmed and whether species identification was done; 3) travel-related or not; 4) treatment details; 5) treatment response and definitions used; 6) adverse events associated with the intervention; 7) relevant information relating to study quality or interpretation. Based on previously conducted SR on New World CL [14], we anticipated that no or very few (high quality) clinical trials would be found, but rather expected a range of small, generally non-randomized (low quality) studies, all with obvious study limitations. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of nonrandomized studies [16]. Three broad perspectives were assessed: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. Clinical trials were evaluated as per standard quality assessment tool for randomized controlled trials in line with recommendations in the Cochrane handbook [17]. Given the nature of extracted data, only simple descriptive analysis was conducted, summarizing the individual studies.

Results

Characteristics of the selected manuscripts and strengths and weaknesses

Out of a total of 95 studies or reports identified and screened, only 27 provided information relevant to our topic (Fig 1). This comprised 13 case series and seven case reports, generally clinical information collected as part of clinical practice. Most of these were reported over 30 to 40 years ago. There were two more recent prospective observational studies whereby a study protocol had been written and patient consent was requested. Since treatment allocation was based on CL type and/or severity, no true comparison in efficacy could be made. Only two small clinical trials were identified, one on tuberculosis drugs and pentamidine reported in 1981 and a small placebo-controlled trial on itraconazole reported in 1990. Three additional studies yielded relevant drug susceptibility information.

In total, outcomes of 506 treatment episodes were reported (excluding one report because of potential overlap). Most commonly used drugs were antimonials ($n = 201$), pentamidine ($n = 150$) and cryotherapy ($n = 103$). The majority of studies reported on patients being treated in *L. aethiopia* endemic regions (one in Kenya, the other in Ethiopia) but only three of these studies did species identification in all reported cases. There were three cases of migrants treated in Europe or Israel. We identified nine studies on LCL cases, seven on DCL and two on MCL cases. In addition, three included LCL and DCL cases, two included LCL and MCL and DCL cases and one included LCL, MCL and DCL patients.

Most studies had obvious limitations, beyond the descriptive nature. Definitions of treatment outcomes varied across studies and were often not clearly defined. Sample size was often small, follow-up short and information on patient characteristics often limited. In formal quality assessment, the non-randomized studies performed poorly, with a median score of three (maximum score is eight), see Table 3. Only the two prospective studies reached a score of five. The oldest clinical trial on tuberculosis drugs and pentamidine had a high risk for blinding of participants/staff and outcome assessment, an unclear risk for bias for random sequence generation, allocation concealment and selective reporting and a low risk for incomplete outcome data. The trial on itraconazole had a low risk for random sequence generation, allocation




Fig 1. Overview of records identified, screened, reviewed and included in the review.

doi:10.1371/journal.pntd.0004495.g001

concealment and blinding of participants/staff and outcome assessment, an unclear risk for bias for selective reporting and a high risk of bias for incomplete outcome data.

Clinical studies on LCL and MCL treatment

We identified a total of 17 clinical studies reporting on treatment of CL or MCL (presumably) due to *L. aethiopia*, relating to 384 treatment episodes (Table 4). There were two small clinical trials, two prospective non-randomized studies and 13 case reports/series. All but two included less than 100 patients. Species identification was systematically done in only six reports. One small placebo-controlled randomized clinical trial (n = 14) evaluated oral itraconazole for LCL and DCL and found it as effective as placebo. In another clinical trial, isoniazid, rifampicin and

Table 3. Assessment of study quality of non-randomized studies using the Newcastle-Ottawa Scale (NOS).

	Treatment group representative	Control group representative	Treatment details given	Outcome not pre-existing	Comparability of groups	Independent outcome ascertainment	Follow up time (≥ 3 months)	Loss to follow up (<10%)	Total score
[7]	*	*	*	*	0	0	*	0	5
[46]	*	*	*	*	0	0	*	0	5
[5]	0	0	*	*	0	0	0	0	2
[47]	0	0	*	*	0	0	*	*	4
[48]	0	0	0	*	0	0	*	*	3
[49]	0	0	0	*	0	0	0	*	2
[50]	0	0	*	*	0	0	0	0	2
[51]	0	0	0	*	0	0	0	0	1
[52]	0	0	*	*	0	0	0	0	2
[53]	0	0	*	*	0	0	0	0	2
[54]	0	0	*	*	0	0	0	0	2
[55]	0	0	*	*	0	0	*	*	4
[56]	0	0	*	*	0	0	0	*	3
[57]	0	0	0	*	0	0	0	0	1
[58]	0	0	*	*	0	0	*	*	4
[59]	0	0	*	*	0	0	0	*	3
[60]	0	0	*	*	0	0	0	0	2
[61,62]	0	0	*	*	0	0	0	*	3
[21]	0	0	*	*	0	0	*	*	4
[63]	0	0	*	*	0	0	0	*	3
[53]	0	0	*	*	0	0	0	*	3
[64]	0	0	0	*	0	0	0	0	1

Three broad perspectives were assessed: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. Stars (*) indicate higher quality.

doi:10.1371/journal.pntd.0004495.t003

amithiozone were compared with pentamidine injections. While only one out of six patients improved with the former treatment, all six cases on pentamidine demonstrated improvement. However, no species identification was done and half of the cases were not parasitologically confirmed.

Two prospective studies including outcomes with antimonials and/or cryotherapy were found. In a study from Tigray, clinical non-response was observed in 23 (15%) of the 154 treated (intralesional or systemic SSG). Failure rates were particularly high in MCL and DCL cases and all of the HIV cases relapsed. In a study in Southern Ethiopia with a main focus on cryotherapy, 20 cases not qualifying for cryotherapy were treated with systemic SSG but two (10%) did not respond clinically. This study mainly included LCL, and most of these were identified during active case finding, which could possibly have led to earlier CL diagnosis. This study is also the only formal evaluation of cryotherapy in Ethiopia, showing cure in 81% of cases. A large case series of cryotherapy from the same centre demonstrated cure rates of 60–70% [5]. In Kenya, three cases unresponsive to standard SSG treatment were successfully treated with a high dose (18–20 mg/kg twice daily for 30 days). *In vitro* data generally suggested a low susceptibility of *L. aethiopia* to antimonials (Table 5).

A number of (often older) studies reported pentamidine—in contrast to antimonials—to be effective against CL (including MCL). However, this were typically case series, reporting on

Table 4. Clinical studies on cutaneous and mucocutaneous leishmaniasis due to *L. aethiopica*.

Ref	Study design; country; year; study population ^a	Patient characteristics	Drug/Intervention	N	Efficacy	Comments
Clinical trials						
[65]	Clinical trial, ALERT Ethiopia; 1981 No species identification	Each group: 1 single LCL histologically diagnosed smear(-)/LST(+); 3 multiple	INH 300 mg, rifampicin 600 mg and amithiozone 150 mg for at least 8 weeks	6	Clinically improved: 1 (at 8 weeks—EOT)	Case that improved was smear(-) at start (histologically
		LCL smear(+)/ LST(+); 2 multiple LCL smear	Pentamidine dimethansulphonate 4	6	All 6 clinically improved and skin smear negative	diagnosed) Treatment allocation
		pos(+)/LST(-) No further details	mg/kg 15 doses alternative days IM		EOT (4 weeks)	not clear: random?
[21]	Placebo-controlled randomized double blind clinical trial ALERT/AHRI Ethiopia; 1990 CL (10) and DCL (4) No species identification	Age 12–48 years	Itraconazole 4 x 50 mg PO daily for 4 weeks Placebo	7 7	EOT: active lesion 7; clinically improved 0 M1 FU: 2/5 improved Parasite culture(-): 2/5 EOT: active lesion 5; clinically improved 2 M1 FU: 4/7 improved Parasite culture(-): 4/7	Itraconazole generally well tolerated None of the DCL patients improved Generation of randomization and concealment of allocation not clear
Main focus antimonials or cryotherapy						
[7]	Prospective evaluation in free NGO CL clinic; Tigray region, Ethiopia 1/2005-7/2007 No species identification	75.3% males; Age 5–14: 40 (24%) Age 15–44: 113 (68%)	LCL: SSG local injection every 3 days/4 weeks DCL, MCL, RCL, PKDL, relapse: MA 20 mg/kg for 30 days IV	154	6M overall outcome: 69% (106) cure; 15% (23) failure; 14% (21) relapse; 4 stopped systemic SSG for toxicity	13 of 167 not treated (11 mild; 2 severe CL) Cure: free from clinical and microbiological All cases presumably parasitologically confirmed (?) HIV coinfection 5.6% (5/89): all relapsed
	LCL (123; 13 not treated)			110	0 non-response, 9 relapse	
	DCL (11)			11	8 non-response; 3 relapse	
	MCL (29)			29	13 non-response; 7 relapse	
	ML (1)			1	1 non-response	11 of 21 relapses:
	PKDL (1)			1	1 non-response	no response to
	RCL (2)			2	0 non-response, 2 relapse	prolonged IV SSG
	DCL; SSG resistant relapse (1)		Pentamidine isothionate (if non response to SSG)	8	7/8 (87% cured) by M6 Cure in MCL and MCL	No intolerance to pentamidine
	MCL; SSG resistant relapse (6)		4 mg/kg every second day till negative		DCL case initially clinically improved;	
	RCL; SSG resistant relapse relapse (1)		aspirate + clinical resolution (~ 20 days)		followed by relapse	
[46]	Non-randomized prospective	Mean age 18.4 years	Liquid nitrogen weekly	103	Cure: 83 (80.6%)	Per protocol cure rate

(Continued)

Table 4. (Continued)

Ref	Study design; country; year; study population ^a	Patient characteristics	Drug/Intervention	N	Efficacy	Comments
	prospective study	Male 53/103	until cure (3–4 sessions		Non-response: 6 (5.8%)	Cryotherapy: 93.3%
	South-Ethiopia (Silti); 11/2008-6/2009	Mean lesion duration: 8.5 months	10–30 sec per lesion per visit)		Dropout: 14 (13.6%)	SSG: 89.5%
	LCL and MCL cases (n = 14) (active & passive case finding)	Mean age 19.6 years Male 14/20	SSG 20 mg/kg/day for 30 days IM—FU?	20	Cure: 17 (85.0%) Non-response: 2 (10.0%)	Cure (M3): ulcers: complete scarring Nodules: flattening
		Mean lesion duration: 13.1 months	(SSG if lesions: > 3; or esthetically sensitive areas; or MCL)		Dropout: 1 (5.0%)	no inflammation
[5]	Case series presented at consultative meeting ALERT/AHRI Addis Abeba, 2001–2006	Total 559 cases 341 male, 218 female Age range 2–70 years 79% lesion in face	Liquid nitrogen Duration variable 4–12 weeks up to > 60 weeks	559	340 discharged cured 114 still on treatment 105 interrupted (16 failing cases found with other pathology)	Partly overlapping with record above [46]
	Confirmed CL cases Unclear about species identification	79% LCL, 4% multiple CL; 17% MCL				
[47]	Case series, Kenya—LCL 1981–1982	Male adults Age: 18, 21, 22 years	SSG 18–20 mg/kg IV twice daily 30 days	3	All patients improved and parasite negative during treatment	No severe toxicity (mainly thrombosis and transient ECG and liver test abnormalities)
	Cases unresponsive to SSG Species identification in One	Lesion duration 5, 7, 9 months			All clinically cured (by M2-M6; one relapse by 1 year; improved with heat therapy	
[48]	Case report Addis Ababa, 1993	Male, 29 years Original lesion treated and cured	SSG 20 mg/kg 30 days		Partial clinical response EOT; cured at M8 Parasitological failure (no change)	1987: LCL cured after SSG 30d; Recurrence (1991): no effect
	Recurrence of LCL due to AIDS in 1987					effect of SSG of SSG 30 days
Main focus pentamidine						
[49]	Case series DCL (2)/LCL(6) combined with leprosy; Addis Abeba, Ethiopia 1965–67; 1974–76	6 males, 2 females Age range 12–30 years	Pentamidine (no details) Cycloguanil paomate	2	DCL: both “responded well” CL (lupoid): “responded well” LCL: all “responded well” No info	2 LCL & 1 lupoid CL Not confirmed 7/8 lepra cases treated (with dapsone) Outcome: “responded well”; relapse in 1 LCL
[50]	Case series, Ethiopia; 1965	Details lacking No sex predominance Onset: age 4–12 years	Pentamidine (Lomidine) IM +/- 1 cc/10 kg every 2 d for 7 doses		General comments: “Antimonials ineffective (SSG 10 cc IM 17 days)”	Despite dramatic improvement with, recrudescence typically

(Continued)

Table 4. (Continued)

Ref	Study design; country; year; study population ^a	Patient characteristics	Drug/Intervention	N	Efficacy	Comments
	No species identification	except one 57 years			Pentamidine: "rapid diminution of lesions"	seen after pentamidine; All parasitologically confirmed?
[51]	Case series, MCL (4) Ethiopia, 1978	3 males, one female Age range 15–49 years	Pentamidine 150 mg IM twice weekly for 8 weeks	2	Pentamidine: "very good response"	Antimonials used in 2 Cases since no pentamidine available
	No species identification		MA (Glucantime) no details	2	MA: "no response"	
[52]	Case series; LCL, DCL ALERT, Ethiopia 5/1981-4/1983	104 pts; 40 females 64 males 74% age 10–39	Pentamidine mesylate (Lomidil) 2–4 mg/kg IM Alternate days		49 LCL and all 6 DCL were treated No efficacy data on LCL	55 pts treated, 20 with severe toxicity; 15 withdrawn PM
	Species identification in part	98 LCL, 6 DCL	Duration not given		DCL: All clinically improved at discharge	(severe nausea, vomiting, hypoglycaemia)
	20	DCL: mean duration 5 years			3 still smear(+)	3 diabetes mellitus; 1 patient
Various						
[53]	Case series, Addis Abeba, Ethiopia, 1978; MCL – parasitologically confirmed;	2 females, 3 males	Metronidazole 3x500 mg 4–8 Weeks	5	No clinical or histological Changes	Remission after treatment with Pentamidine Isethionate
	No species identification					No serious side effects
[54]	Case series; LCL, Wollega province Ethiopia, 1968	No details	Cycloguanil pamoate (CI-501; Camolar) 2x2.5 ml IM (2x 350 mg = twice the dose for malaria treatment) lower for children; repeated at 6 weeks in 10 pts	30	20 pts were reviewed at FU: improved (2); no change (8); ambiguous (3) ie both signs of worsening/improvement; worsening (7)	Not all cases parasitologically confirmed; Pts that improved had not been parasitologically confirmed
[55]	Case report, LCL case having lived in Tigray region, Ethiopia Lesion onset 1982, Ketoconazole given 1984	51 year old non, lesion duration: 27 Months	Ketoconazole dose of 200 mg b.i.d. for 4 weeks	1	EOT: lesion 50% Reduction By 2.5 months after treatment: cure/lesion healed	Minimal response with 4 weeks application of Pentamidine dimethylsulfoxide gel No relapse at 12M
	No species identification					
Ethiopian/Eritrean migrants or travelers^[54]						
[56]	Case report LCL in Ethiopian patients migrated to Israel, 1987	Two children (both female), one male One case first treated with keto conazole 50mg/d	Ointment containing 15% paromomycin sulphate and 12% methylbenzethonium chloride in white soft paraffin—applied twice	1	All parasitologically cured at ten days All clinically cured but (end of treatment extended in two (10–30 days)	Two developed allergic contact dermatitis

(Continued)

Table 4. (Continued)

Ref	Study design; country; year; study population ^a	Patient characteristics	Drug/Intervention	N	Efficacy	Comments
		for 4 weeks	daily for 10 days		since at day 10 no clinical improvement	
[57]	Case report, LCL	No details	Miltefosine—No details	1	Clinically cured	CL probably acquired in Egypt
[58]	Case report	38-year old, LCL in Eritrean man	Liposomal amphotericin B	1	Clinically improved by 3 weeks; clinically cured at	On infliximab, methotrexate,
	travelled to Germany	Immunosuppressed male patient	60 mg/kg body weight in doses of 200 mg/day for 2		12 month follow-up visit	and prednisolone for
		6x5 cm facial lesion	2 days (2.5–3 mg/kg/d x 22); total dose 4.4 gram			rheumatoid arthritis

^aIf the study period is not given, the year of publication is represented; cases parasitologically confirmed unless specified otherwise; species confirmation done (*L. aethiopia*) unless specified otherwise

ALERT: All Africa Leprosy Rehabilitation and Training Center; AHRI: Armauer Hansen Research Institute; DCL: diffuse cutaneous leishmaniasis; EOT: end of treatment; IM: intramuscular; INH: isoniazid; LCL: localised cutaneous leishmaniasis; LST: Leishmania skin test; MA: meglumine antimonite; PO: per os; 1M FU: one month follow up; SSG: sodium stibogluconate

doi:10.1371/journal.pntd.0004495.t004

patients from routine clinical practice and without standardized outcome reporting. Pentamidine also appeared effective in the above mentioned clinical trial and in the complicated CL cases (CL relapse not responding to SSG including MCL) in the prospective study from Tigray [7]. We identified one case study of LCL treated with ketoconazole, with 50% lesion reduction at the end of treatment and cure 2.5 months later.

Several small studies reported on treatment in countries outside Ethiopia. Paromomycin ointment was highly effective in three Ethiopians treated in Israel. As to miltefosine, one case of successful treatment was reported in Germany. Of interest, miltefosine has been successfully used in more than 50 CL cases due to *L. aethiopia* in Addis Ababa, but the findings have not been published (personal communication, Asrat Hailu). Liposomal amphotericin B was found effective in one immunosuppressed Eritrean patient treated in Germany.

Four studies included MCL patients. Metronidazole was ineffective in five cases of MCL. Antimonials were usually not found effective, but better outcomes were generally observed with pentamidine.

The available *in vitro* data relating to these drugs suggest a good susceptibility of *L. aethiopia* to miltefosine, paromomycin, pentamidine and amphotericin B (Table 5). The most recent study by Utaile *et al* was conducted in Ethiopia using strains isolated from patients [18]. Parasite susceptibility was highest for Ambisome (in the sub-micromolar range), followed by miltefosine with an IC₅₀ of 5.88 µg/ml. Efficacy of miltefosine against visceral leishmaniasis and other CL-causing species was exerted in a similar low micromolar range. Miltefosine had the highest maximal efficacy against CL, MCL and DL. Paromomycin had the highest IC₅₀ but had the second highest maximal efficacy against MCL and CL strains. Two other studies used reference strains. In the study by Escobar *et al*, amphotericin B was again active at low concentrations; the ED₅₀ for miltefosine was less than 5 µM [19]. In a third study, pentamidine had the lowest ED₅₀ (0.6 µM), followed by paromomycin (ED₅₀ 6.4 µM) [20]. In another study, paromomycin was evaluated against three strains, with ED₅₀ of 4.0–15.0 µg/ml before treatment

Table 5. Drug susceptibility studies on *L. aethiopia*.

Ref	Assay; parasite strains	IC50 or ED50	Comments
[18]	Amastigote-macrophage <i>in vitro</i> model—CD1 mouse	IC50 (µg/ml ± SD)	MF: maximal efficacy against all three forms; followed by ampho against LCL; by PM against DCL/ML;
	derived PEMs	- Ampho: 0.16 ± 0.18	DCL/ML generally less sensitive
	Patient strains:	- MF: 5.88 ± 4.79	
	LCL: 8; MCL: 9; DCL: 7	- SSG: 10.23 ± 8.12	
		- Paromo: 13.63 ± 18.74	
[20]	Human leukemia monocyte cell line THP-1 MHOM/ET/72/L100 strain	ED50: - SSG: 25.3 µg SbV/ml; - PM: 0.6 µM - Paromo: 6.4 µM	<i>L. aethiopia</i> less sensitive to SSG than <i>L. donovani</i>
[19]	Promastigote assay; Amastigote-macrophage assay (peritoneal CD1 mouse macrophages) MHOM/ET/84/KH strain	Promastigote (ED50-µM) - MF: 1.16–2.76 - Edelfosine: 0.62–1.28 - Ampho: 0.11–0.24 Amastigote (ED50-µM) - MF: 2.63–4.92 - Edelfosine: 1.15–2.92 - Ampho: 0.04–0.07	Ampho most active (submicromolar concentration) Tested in parallel: L Major generally least susceptible, <i>L. donovani</i> most susceptible
[21]	THP-1 monocyte cell line	1) ED50: 4.0 µg/mL (pre-treatment); 21.9 µg/mL (at relapse);	ED50 for SSG high: 78.2 µg Sb/ml (pt 1); 55.0 µg (pt 2)
	Patient strains (DCL-Ethiopia); Two patients (1,2) treated with PM and subsequent relapse, improving on PM/SSG	2) ED50: 7.1 µg/mL (pre-treatment); 21.3 µg/mL (at relapse)–	Sb/ml synergism with SSG in both patients
	Patient 3 treated with PM/SSG	3) ED50: 15.0 µg/mL (pre-treatment)	

ampho: amphotericin B deoxycholate; DCL: diffuse cutaneous leishmaniasis (CL); ED50: effective dose 50; IC50: inhibitory dose 50; LCL: localized CL; MCL mucocutaneous leishmaniasis; MF: miltefosine;; Paromo: paromomycin; PEM: Peritoneal exudate macrophages; PM: pentamidine; SSG: sodium stibogluconate; Sb: pentavalent antimonial.

doi:10.1371/journal.pntd.0004495.t005

[21]. Antimonials were only active at high concentrations, but exerted synergism with PM which correlated with the clinical response.

Clinical studies on DCL treatment

As to treatment with pentamidine, we found data on 62 patients in a total of ten studies (Table 6). The largest group of patients stems from pioneering work done by Bryceson and colleagues in the late sixties, reporting on 31 patients treated with varying regimens of pentamidine. Of 24 patients receiving pentamidine daily or every other day in the study by Bryceson, all improved during treatment although none was cured. However, frequent pentamidine administration was associated with substantial toxicity. With less frequent administration, safety was improved at the expense of efficacy. An additional four cases were reported in four other studies, all showing clinical improvement.

Outcomes with systemic antimonials were reported in 38 cases, of which only nine demonstrated clinical response. A prolonged course of paromomycin was successful in treating two

Table 6. Clinical studies specifically focused on diffuse cutaneous leishmaniasis due to *L. aethiopia*.

Ref	Study design; country; year; study population ^a	Patient characteristics	Drug/Intervention	N	Efficacy	Comments
[59]	Case series; DCL Ethiopia; 1982	Female, 28 years	Pentamidine	1	Clinical, histological and parasitological improvement by EOT (no "cure")	No info on toxicity
		DCL for 2 years	dimethane sulphonate			Male pt had been treated with
		Male, 35 years, DCL for 10 year	200 mg (Lomidine) daily IM for two weeks			pentamidine before but had relapsed
[60]	Case series; DCL Ethiopia; 1970 No species identification		Pentamidine dimethansulphonate 4 mg/kg (Lomidine)	31	31 improved (7 cured)	Cure: clinic- parasitological
			- Daily or alternative days (4–23 doses); TD 1–3.4g	24	24 improved (0 cured)	resolution; Improved:
					13 relapse	clinical improvement;
			- Weekly (4–21 weeks); TD 0.7– 2.4g	12	11 improved (1 cured)	Relapse common; Most
			- Every two weeks (2–10w)	9	6 improved (2 cured)	toxicity with PM &
			- Monthly (5–6 months)	5	3 relapses; 2 lost	amphotericin B; dose-
			Pentostam: 10–20 mg/kg 5–30 days, TD 3–17 gr	17	0 improved 0	limiting toxicity with
			Glucantime: 10–21 days; 12 mg/ kg 10–21 days (TD 3–12.6 gr)	8	4 improved	frequently doses PM
			SSG + pentamidine	16	12 improved (4 cured)	Other drugs tested (no
			(for relapse after SSG) alternating 10 doses each (2–8 weeks)		6 relapsed	convincing effects): high dose antimalarials; astiban macrocydon,
	Amphotericin B 1 mg/kg on alternating days (29–48 mg/kg TD over 3–5 months)	4	4 improved 4 (1 cured)	Griseofulvine		
[61,62]	Case report DCL relapse after PM Previously transient DM with Lomisil (pentamidine mesylate) AHRI, Ethiopia; 1978	40 year old female	PM isethionate 200 mg IM every every 2 d for one month		Marked reduction in reduclinimprovement, parasite load; no DM Subsequent relapse treated with Lomisil: developed DM	Mention >100 CL cases
		DCL since 25 years				PM treated 1974– 79
		Non-response to				PM isethionate 200 mg IM
		MA, metronidazole				daily 15 days: no DM
		dapsone,				Lomisil period 1979–80
	Chloroquine				DM in 2/30 in 2 year	
	Clofazimine					
[21]	Case series, DCL Addis Ababa, Ethiopia, 1990–1992	Male (2)	Paromo 14 mg/kg 60 days (2 cases of DCL) (reduced to 12 mg/kg	2	EOT complete clinico- parasitological resolution	Relapse after 1 and 3 months; subsequently Treated with paramo +

(Continued)

Table 6. (Continued)

Ref	Study design; country; year; study population ^a	Patient characteristics	Drug/Intervention	N	Efficacy	Comments
	No species identification		3x/weeks in one pt due to renal dysfunction			SOG
		Male (2); female (1)	Paromo 14 mg/kg + SOG	3	EOT complete clinico-parasitological resolution	Relapse free at 17, 21 months; Audiograms normal
			10 mg/kg 2 months-beyond parasitological cure (6–9 months; 2 patients)			PM dose reduction in relapsing after paromo (see above) + 1 new patient
[63]	Case series, DCL	Three (no details)	Chlorpromazine 2% ointment for one month	3	All became smear neg	No long term outcome
	Addis Ababa, Ethiopia; 1983				Inflammation disappeared (3); regression of affected area (1)	All three confirmed parasitologically
[53]	Case series, DCL	Two (no details)	Metronidazole—no details	2	Initial clinical improvement;	No complete remission
	Addis Ababa; 1978		Given		histologically confirmed: 1	
[64]	Case series, DCL	Atypical DCL (n = 2);	MA 28 days IM	2	Clinical improvement	One case received
	Mekele; 2013	alike borderline-tuberculoid leprosy			EOT	a second treatment course for consolidation
	No species identification	Males (18, 20 years)				

^aIf the study period is not given, the year of publication is represented; cases parasitologically confirmed unless specified otherwise; species confirmation done (*L. aethiopia*) unless specified otherwise

ALERT: All Africa Leprosy Rehabilitation and Training Center; AHRI: Armauer Hansen Research Institute; DCL: diffuse cutaneous leishmaniasis; EOT: end of treatment; IM: intramuscular; INH: isoniazid; LCL: localised cutaneous leishmaniasis; LST: Leishmania skin test; MA: meglumine antimonite; PO: per os; 1M FU: one month follow up; SOG: sodium stibogluconate

doi:10.1371/journal.pntd.0004495.t006

cases of DCL, although both relapsed [21]. Three patients (including these two relapse cases) have been successfully treated with an extended course of paromomycin combined with SOG. Good susceptibility to paromomycin, poor susceptibility to antimonials but synergism between SOG and paromomycin could be demonstrated *in vitro* [21]. In the study by Bryceson, sixteen individuals were treated with antimonials and pentamidine in combination. Twelve improved during treatment, seven were declared cured. In the same study, all four cases treated with conventional amphotericin B treatment improved, but toxicity was substantial.

Metronidazole was tried in two patients, who displayed clinical improvement. As mentioned above, itraconazole was generally not found to be effective. Chlorpromazine ointment displayed some effect in a small case series, reported over 30 years ago.

Table 7. Ethiopian and WHO guidelines for treatment of cutaneous leishmaniasis in Ethiopia.

	National guidelines	WHO guidelines
Local Therapy	- Intra-lesion SSG weekly for four to six weeks	Several options but indicating limited evidence base
	- Cryotherapy	- Cryotherapy or intra-lesional
	- Curetage ^a	SSG (alone or combined)
	- Heat therapy ^a	- Thermotherapy
	- Topical ointment ^a	- Topical ointment
Systemic therapy	- Paromomycin 14–15mg (sulphate)/ kg for 20–30 days	- 20 mg of Sb5+/kg/d IM or IV for 28 days
	- 20mg Sb5+/kg/day IM or IV for 4–8 weeks	
	- Miltefosine ^a	
Diffuse CL	- Liposomal amphotericin B ^a	
	- Paromomycin 15mg/kg + SSG 10mg/kg	- 20 mg of Sb5+/kg/d IM or IV for 28 days + Paromomycin 15 mg/kg/day IM for 60 days or longer (C) - Pentamidine isethionate 3–4 mg/kg/d IV once or twice weekly (up to 4 months) (C)

Level of Evidence (C): Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees

^a guideline stipulates these have not yet been used for CL in Ethiopia

CL: cutaneous leishmaniasis; IM: intramuscular; IV: intravenous; SSG: sodium stibugluconate

Sb5+: pentavalent antimonial

doi:10.1371/journal.pntd.0004495.t007

Discussion

The evidence base for treatment of CL due to *L. aethiopia* remains extremely poor. Most studies were conducted decades ago, including often involving a few patients, lacking appropriate control groups and usually not employing a well-defined and rigid methodology. Outcome measures varied widely across the different reports. In drug susceptibility studies, pentamidine, paromomycin, amphotericin and miltefosine looked most promising. Antimonials were only effective *in vitro* at relatively high doses. Some studies supported the efficacy of antimonials against LCL, others reported on the poor efficacy. Both the national and WHO recommend topical or systemic administration of antimonials for LCL treatment in Ethiopia (Table 7) and, despite the lack of a good evidence base, antimonials remain the most widely available anti-leishmanial drug in Ethiopia. Given the common and sometimes severe toxicity of antimonials, better defining its efficacy against CL in clinical trials is urgently needed.

The national guidelines recommend intramuscular paromomycin as the preferential LCL first line treatment. This is backed-up by *in vitro* data, although clinical evidence is very scarce with only a small case series on DCL and no reports on LCL caused by *L. aethiopia*. Its good safety profile and availability in Ethiopia argue for its evaluation in clinical trials. At a dose of 12–18 mg/kg/day for 14 days, cure rates of over 90% were obtained in Brazil [22], but only 50–60% in Colombia and in Belize [23,24].

Clinical efficacy of miltefosine has varied globally according to the etiological species and geographical area. In drug susceptibility testing, miltefosine looked promising against *L. aethiopia*, warranting clinical studies. Miltefosine is now increasingly available in East-Africa for VL treatment, creating opportunities for CL as well. Few studies are available on the use of miltefosine against other species causing Old World CL. In one trial from Iran, miltefosine was found as effective as intralesional antimonials against CL caused by *L. major* [25]. As to New World LCL, the efficacy of miltefosine varied across regions and/or species [26].

Although pentamidine appeared effective in antimonial-resistant complicated CL, given its safety profile, it would probably only be considered as second line treatment for LCL. Given

their ready availability in resource-limited settings (often via HIV programs), the efficacy of drugs such as ketoconazole and fluconazole merit further exploration.

Data on the efficacy of topical and physical therapies are very limited. Only cryotherapy and intralesional antimonials have to some extent been evaluated against CL in Ethiopia. Other topical (e.g., paromomycin) and physical therapies might be worth exploring, particular if easy to administer and if implementable in remote settings with limited well-trained health care staff. Recent findings with thermotherapy from Peru are modestly encouraging [27]. Topical application of amphotericin B is currently in early clinical evaluation by the Drugs for Neglected Diseases initiative (DNDi) against *L. braziliensis* and *L. tropica* (www.dndi.org). If promising, this should be expanded to *L. aethiopia*.

Treatment of DCL has been notoriously difficult. While there have been only a few studies on pentamidine, available data seem to indicate a relatively good efficacy, although relapse was commonly observed after pentamidine discontinuation. While toxicity has been a critical concern issue with daily administration (for instance as treatment for human African trypanosomiasis), less frequent administration (e.g., every other day) appeared to be well tolerated while still effective. The WHO recommendations also include pentamidine for DCL treatment. Nevertheless, cumulative toxicity remains a concern, especially as to the risk of diabetes [28,29]. Eight cases of diabetes have been reported from Ethiopia, presumably related to pentamidine use, also in cases that received less frequent administration. However, it is important to note that in the earlier studies pentamidine mesylate (Lomidine) was used, labelled according to the base-moiety (120 mg base per ampoule) with a recommended dose of 4 mg base/kg body weight. Currently, pentamidine isethionate (Pentacarinat or Pentam) is used, labelled according to the amount of salt in the preparation (300 mg salt per ampoule) with a recommended dose of 4 mg of salt/kg. In practical terms, this means that earlier studies employed a higher dose (7 mg of salt/kg) than currently being advised by the company (4 mg of salt/kg) [30]. While possibly leading to improved tolerance, it is unclear to what extent efficacy would be compromised. Nevertheless, the potential risk of diabetes and other adverse effects requires close clinical and laboratory monitoring, restricting its' use to better established health facilities.

Both the WHO and national guidelines include the combination of paromomycin and antimonials for DCL treatment, albeit with different dosing of the antimonials and acknowledging the limited evidence base. This combination now constitutes the first line VL treatment in VL endemic east African countries, which would facilitate its implementation if found effective. Nevertheless, a daily parenteral treatment regimen of at least two months remains cumbersome and can only be seen as a short-term solution. Paromomycin and miltefosine in combination would also be worth evaluating. Miltefosine was found effective against DCL in a small study conducted in Venezuela, with most cases caused by *Leishmania amazonensis*, although all but one subsequently relapsed [31]. This combination (given for ten days) has been found safe and effective against visceral leishmaniasis in India [32].

Even if more potent drugs for DCL would be identified, most cases are likely to relapse after treatment discontinuation, unless the underlying immunosuppression can be altered. This provides the rationale for complementary approaches such as adjuvant immunotherapy. Effective treatment of DCL will most likely require adjuvant strategies such as immunotherapy to consolidate the treatment response. Therapeutic vaccination with first generation vaccines—has been found effective against DCL and ML in the New World [33,34], but has not yet been explored in Ethiopia. Moreover, second generation vaccines have been developed [35], which looked promising in phase I studies against New World CL and ML [36,37]. DNDi (www.dndi.org) is currently exploring the use of CpG-DNA [38–42] for CL due to *L. braziliensis* and *L. tropica*. An interesting approach could combine chemotherapy with therapeutic vaccination with a second generation vaccine and/or CpG-DNA against the different forms of CL.

Trials should probably initially focus on LCL and possibly MCL, since this is the predominant clinical presentation. However, efforts should also be made to provide treatment to more complicated manifestations within clinical trials such as DCL (e.g., via a compassionate use protocol in a well-documented case series). Given the lack of quality data on any of the available treatments, several potentially interesting interventions should be evaluated in future clinical trials, with the most promising ones taken further in more extensive evaluations. Adaptive clinical trial designs have been increasingly used in NTDs, since these have the potential to more quickly and efficiently weed out ineffective regimens across the different intervention arms [43,44]. For non-complicated LCL, various topical or physical therapies should be evaluated.

As to systemic treatment for complicated CL, interventions to be prioritized for evaluation include paromomycin, miltefosine and antimonials (possibly combined with paromomycin). While the higher cost of liposomal amphotericin B is an obvious disadvantage, price reductions (e.g. via generics) remain possible and the drug is increasingly available in VL endemic countries [45].

In conclusion, the evidence-base for treatment of CL due to *L. aethiopia* is extremely limited, warranting prospective clinical studies. While antimonials might for the time being remain the cornerstone of CL treatment, not in the least because of their availability and clinical experience within Ethiopia, their efficacy and safety in CL should be better defined. Most importantly, alternative first line treatments should be explored, preferably topically or to be taken orally. As to DCL, the options appear limited. Pentamidine appears most promising, but toxicity is an issue. High quality trials on CL due to *L. aethiopia* are urgently needed. A good scenario would be several options in parallel using adaptive designs/group sequential methods to discontinue the arms with ineffective drugs.

Supporting Information

S1 Checklist. PRISMA Checklist.
(DOC)

Author Contributions

Conceived and designed the experiments: JvG ED. Performed the experiments: JvG ED. Analyzed the data: JvG ED EG AH AA AMB. Wrote the paper: JvG ED AA AH EG AMB.

References

1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. *Lancet Infect Dis* 7: 581–596. PMID: [17714672](#)
2. Goto H, Lindoso JA (2010) Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. *Expert Rev Anti Infect Ther* 8: 419–433. doi: [10.1586/eri.10.19](#) PMID: [20377337](#)
3. Strazzulla A, Cocuzza S, Pinzone MR, Postorino MC, Cosentino S, et al. (2013) Mucosal leishmaniasis: an underestimated presentation of a neglected disease. *Biomed Res Int* 2013: 805108. doi: [10.1155/2013/805108](#) PMID: [23853773](#)
4. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* 7: e35671. doi: [10.1371/journal.pone.0035671](#) PMID: [22693548](#)
5. (2011) Proceedings of the international consultative meeting on cutaneous leishmaniasis in Ethiopia; Addis Ababa, July 4–5, 2011: Leish-mapping team at AHRI in collaboration with WHO-Ethiopia.
6. Seid A, Gadisa E, Tsegaw T, Abera A, Teshome A, et al. (2014) Risk map for cutaneous leishmaniasis in Ethiopia based on environmental factors as revealed by geographical information systems and statistics. *Geospat Health* 8: 377–387. PMID: [24893015](#)
7. Padovese V, Terranova M, Toma L, Barnabas GA, Morrone A (2009) Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. *Trans R Soc Trop Med Hyg* 103: 707–711. doi: [10.1016/j.trstmh.2009.02.023](#) PMID: [19356780](#)

8. Lemma A, Foster WA, Gemetchu T, Preston PM, Bryceson A, et al. (1969) Studies on leishmaniasis in Ethiopia. I. Preliminary investigations into the epidemiology of cutaneous leishmaniasis in the highlands. *Ann Trop Med Parasitol* 63: 455–472. PMID: [5394018](#)
9. Ashford RW, Bray MA, Hutchinson MP, Bray RS (1973) The epidemiology of cutaneous leishmaniasis in Ethiopia. *Trans R Soc Trop Med Hyg* 67: 568–601. PMID: [4150462](#)
10. Mengistu G, Laskay T, Gemetchu T, Humber D, Ersamo M, et al. (1992) Cutaneous leishmaniasis in south-western Ethiopia: Ocholo revisited. *Trans R Soc Trop Med Hyg* 86: 149–153. PMID: [1440773](#)
11. Negera E, Gadisa E, Yamuah L, Engers H, Hussein J, et al. (2008) Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. *Trans R Soc Trop Med Hyg* 102: 883–890. doi: [10.1016/j.trstmh.2008.03.021](#) PMID: [18479722](#)
12. Pralong F, Dereure J, Ravel C, Lami P, Balard Y, et al. (2009) Geographical distribution and epidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains. *Trop Med Int Health* 14: 1071–1085. doi: [10.1111/j.1365-3156.2009.02336.x](#) PMID: [19624480](#)
13. Caneda-Guzman IC, Salaiza-Suazo N, Fernandez-Figueroa EA, Carrada-Figueroa G, Aguirre-Garcia M, et al. (2014) NK cell activity differs between patients with localized and diffuse cutaneous leishmaniasis infected with *Leishmania mexicana*: a comparative study of TLRs and cytokines. *PLoS One* 9: e112410. doi: [10.1371/journal.pone.0112410](#) PMID: [25397678](#)
14. Gonzalez U, Pinart M, Reveiz L, Alvar J (2008) Interventions for Old World cutaneous leishmaniasis. *Cochrane Database Syst Rev*: CD005067. doi: [10.1002/14651858.CD005067.pub3](#) PMID: [18843677](#)
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 339: b2700. doi: [10.1136/bmj.b2700](#) PMID: [19622552](#)
16. Wells GS, B; O'Connell, D; Peterson, J; Welch, V; Losos, M; Tugwell, P (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
17. Higgins JG, S (2011) *Cochrane handbook for systematic reviews of interventions*, version 5.1.0. The Cochrane collaboration.
18. Utaile M, Kassahun A, Abebe T, Hailu A (2013) Susceptibility of clinical isolates of *Leishmania aethiopia* to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model. *Exp Parasitol* 134: 68–75. doi: [10.1016/j.exppara.2013.01.022](#) PMID: [23434530](#)
19. Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of *Leishmania* species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. *Acta Trop* 81: 151–157. PMID: [11801222](#)
20. Gebre-Hiwot A, Tadesse G, Croft SL, Frommel D (1992) An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. *Acta Trop* 51: 237–245. PMID: [1359751](#)
21. Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, et al. (1994) Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by *Leishmania aethiopia*. *Trans R Soc Trop Med Hyg* 88: 334–339. PMID: [7974682](#)
22. Correia D, Macedo VO, Carvalho EM, Barral A, Magalhaes AV, et al. (1996) [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by *Leishmania* (*Viannia*) *braziliensis*]. *Rev Soc Bras Med Trop* 29: 447–453. PMID: [8966308](#)
23. Soto J, Grogl M, Berman J, Oliario P (1994) Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. *Trans R Soc Trop Med Hyg* 88: 695–698. PMID: [7886777](#)
24. Hepburn NC, Tidman MJ, Hunter JA (1994) Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. *Trans R Soc Trop Med Hyg* 88: 700–703. PMID: [7886779](#)
25. Mohebal M, Fotouhi A, Hooshmand B, Zarei Z, Akhouni B, et al. (2007) Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. *Acta Trop* 103: 33–40. PMID: [17586452](#)
26. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, et al. (2009) Interventions for American cutaneous and mucocutaneous leishmaniasis. *Cochrane Database Syst Rev*: CD004834. doi: [10.1002/14651858.CD004834.pub2](#) PMID: [19370612](#)
27. Valencia BM, Miller D, Witzig RS, Boggild AK, Llanos-Cuentas A (2013) Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru. *PLoS Negl Trop Dis* 7: e2196. doi: [10.1371/journal.pntd.0002196](#) PMID: [23658851](#)
28. Bryceson A (1968) Pentamidine-induced diabetes mellitus. *East Afr Med J* 45: 110–117. PMID: [5658185](#)

29. Bryceson A, Woodstock L (1969) The cumulative effect of pentamidine dimethanesulphonate on the blood sugar. *East Afr Med J* 46: 170–173. PMID: [5800412](#)
30. Dorlo TP, Kager PA (2008) Pentamidine dosage: a base/salt confusion. *PLoS Negl Trop Dis* 2: e225. doi: [10.1371/journal.pntd.0000225](#) PMID: [18509543](#)
31. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, et al. (2007) Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. *Br J Dermatol* 156: 1328–1335. PMID: [17441955](#)
32. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, et al. (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. *Lancet* 377: 477–486. doi: [10.1016/S0140-6736\(10\)62050-8](#) PMID: [21255828](#)
33. Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, et al. (2004) Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized *Leishmania promastigotes* and bacillus Calmette-Guerin: preliminary report. *Mem Inst Oswaldo Cruz* 99: 57–62. PMID: [15057348](#)
34. Badaro R, Lobo I, Munos A, Netto EM, Modabber F, et al. (2006) Immunotherapy for drug-refractory mucosal leishmaniasis. *J Infect Dis* 194: 1151–1159. PMID: [16991091](#)
35. Duthie MS, Raman VS, Piazza FM, Reed SG (2012) The development and clinical evaluation of second-generation leishmaniasis vaccines. *Vaccine* 30: 134–141. doi: [10.1016/j.vaccine.2011.11.005](#) PMID: [22085553](#)
36. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. *Vaccine* 28: 7427–7435. doi: [10.1016/j.vaccine.2010.08.092](#) PMID: [20851080](#)
37. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. *Vaccine* 28: 6581–6587. doi: [10.1016/j.vaccine.2010.07.063](#) PMID: [20688040](#)
38. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, et al. (2002) CpG oligodeoxynucleotides as vaccine adjuvants in primates. *J Immunol* 168: 1659–1663. PMID: [11823494](#)
39. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM (2011) CpG DNA as a vaccine adjuvant. *Expert Rev Vaccines* 10: 499–511. doi: [10.1586/erv.10.174](#) PMID: [21506647](#)
40. Gupta S, Sane SA, Shakya N, Vishwakarma P, Haq W (2011) CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. *Antimicrob Agents Chemother* 55: 3461–3464. doi: [10.1128/AAC.00137-11](#) PMID: [21537026](#)
41. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, et al. (2010) Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. *J Immunol* 185: 1701–1710. doi: [10.4049/jimmunol.1000238](#) PMID: [20601594](#)
42. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM (2001) Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. *J Immunol* 166: 2372–2377. PMID: [11160295](#)
43. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, et al. (2013) Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. *PLoS Negl Trop Dis* 7: e2130. doi: [10.1371/journal.pntd.0002130](#) PMID: [23556016](#)
44. Olliaro P, Vaillant MT, Sundar S, Balasegaram M (2012) More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. *PLoS Negl Trop Dis* 6: e1545. doi: [10.1371/journal.pntd.0001545](#) PMID: [22666508](#)
45. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. *Expert Opin Emerg Drugs* 17: 493–510. doi: [10.1517/14728214.2012.748036](#) PMID: [23167833](#)
46. Negera E, Gadisa E, Hussein J, Engers H, Kuru T, et al. (2012) Treatment response of cutaneous leishmaniasis due to *Leishmania aethiopia* to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. *Trans R Soc Trop Med Hyg* 106: 496–503. doi: [10.1016/j.trstmh.2012.02.006](#) PMID: [22503475](#)
47. Chulay JD, Anzeze EM, Koeh DK, Bryceson AD (1983) High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. *Trans R Soc Trop Med Hyg* 77: 717–721. PMID: [6318408](#)
48. Berhe N, Hailu A, Gemetchu T (1995) Human immunodeficiency virus and recurrence of cutaneous leishmaniasis long after healed localized cutaneous leishmaniasis due to *Leishmania aethiopia*. *Trans R Soc Trop Med Hyg* 89: 400–401. PMID: [7570878](#)
49. Barnetson RS, Bryceson AD (1978) Cutaneous leishmaniasis and leprosy. *Trans R Soc Trop Med Hyg* 72: 160–163. PMID: [653788](#)
50. Price EW, Fitzherbert M (1965) Cutaneous leishmaniasis in Ethiopia. *Ethiop Med J* 3: 57–83.

51. Barnetson RS, Ridley RS, Wheate HW (1978) A form of muco-cutaneous leishmaniasis in the Old World. *Trans R Soc Trop Med Hyg* 72: 516–518. PMID: [725998](#)
52. Sarojini PA, Humber DP, Yemane-Berhan T, Fekete E, Belehu A, et al. (1984) Cutaneous leishmaniasis cases seen in two years at the All Africa Leprosy and Rehabilitation Training Centre Hospital. *Ethiop Med J* 22: 7–11. PMID: [6690307](#)
53. Belehu A, Naafs B, Touw-Langendijk E (1978) Failure of metronidazole treatment in Ethiopian mucocutaneous leishmaniasis. *Br J Dermatol* 99: 421–422. PMID: [708614](#)
54. Bryceson A, Foster WA, Lemma A (1969) Clinical trial of CI-501 (Camolar) against cutaneous leishmaniasis in Ethiopia. *Trans R Soc Trop Med Hyg* 63: 152–153.
55. Viallet J, MacLean JD, Robson H (1986) Response to ketoconazole in two cases of longstanding cutaneous leishmaniasis. *Am J Trop Med Hyg* 35: 491–495. PMID: [3706620](#)
56. Weinrauch L, Katz M, el-On J (1987) Leishmania aethiopia: topical treatment with paromomycin and methylbenzethonium chloride ointment. *J Am Acad Dermatol* 16: 1268–1270. PMID: [3597872](#)
57. Mosimann V, Neumayr A, Hatz C, Blum JA (2013) Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. *Infection* 41: 1177–1182. doi: [10.1007/s15010-013-0500-5](#) PMID: [23835701](#)
58. Zanger P, Kotter I, Raible A, Gelanew T, Schonian G, et al. (2011) Case report: Successful treatment of cutaneous leishmaniasis caused by *Leishmania aethiopia* with liposomal amphotericin B in an immunocompromised traveler returning from Eritrea. *Am J Trop Med Hyg* 84: 692–694. doi: [10.4269/ajtmh.2011.10-0712](#) PMID: [21540377](#)
59. Zaar K, Wunderlich F, Belehu A (1982) Electron microscopical studies on cutaneous leishmaniasis in Ethiopia. I. The diffuse form and its treatment with pentamidine. *Ann Trop Med Parasitol* 76: 595–605. PMID: [7171248](#)
60. Bryceson AD (1970) Diffuse cutaneous leishmaniasis in Ethiopia. II. Treatment. *Trans R Soc Trop Med Hyg* 64: 369–379. PMID: [5453496](#)
61. Belehu A, Naafs B (1982) Diabetes mellitus associated with pentamidine mesylate. *Lancet* 1: 1463–1464.
62. Naafs B (1985) Pentamidine-induced diabetes mellitus. *Trans R Soc Trop Med Hyg* 79: 141.
63. Henriksen TH, Lende S (1983) Treatment of diffuse cutaneous leishmaniasis with chlorpromazine ointment. *Lancet* 1: 126.
64. Dassoni F, Abebe Z, Naafs B, Morrone A (2013) Cutaneous and mucocutaneous leishmaniasis resembling borderline-tuberculoid leprosy: a new clinical presentation? *Acta Derm Venereol* 93: 74–77. doi: [10.2340/00015555-1338](#) PMID: [22434112](#)
65. van der Meulen J, Mock B, Fekete E, Sarojini PA (1981) Limited therapeutic action of rifampicin/isoniazid against *Leishmania aethiopia*. *Lancet* 2: 197–198.